---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006713"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:52:38.948588+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023

## Summary
- Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.
- Cash and investments $204.2M at year-end; runway expected into first half 2025.
- TN-201 IND for MYBPC3 gene therapy cleared by FDA; Phase 1b dosing planned Q3 2023.
- TN-301 MAD stage dosing commenced; Phase 1 data from SAD/MAD expected H2 2023.
- TN-401 (PKP2 gene therapy) IND submission planned for H2 2023.

## SEC filing metadata
- accession: 0000950170-23-006713
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/0000950170-23-006713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/tnya-20230308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006713
- JSON: https://secwatch.observer/filing/0000950170-23-006713.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006713.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20
  - Result: reported results
  source text: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/0000950170-23-006713-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.